These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the efficacy or safety of Jakafi, the acceptance of Jakafi in the marketplace, risks related to market competition, the results of further research and development, risks and uncertainties associated with sales, marketing and distribution requirements, risks that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards, the ability to enroll sufficient numbers of subjects in clinical trials, other market or economic factors and technological advances, unanticipated delays, the ability of Incyte to compete against parties with greater financial or other resources, risks associated with Incyte's dependence on its relationships with its collaboration partners, and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our Form 10-Q for the quarter ended June 30, 2012.Incyte disclaims any intent or obligation to update these forward-looking statements.
|Condensed Consolidated Statements of Operations|
|(in thousands, except per share amounts)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Product revenues, net||$||43,695||$||-||$||92,700||$||-|
|Costs and expenses:|
|Cost of product revenues||31||-||58||-|
|Research and development||50,079||44,604||150,627||126,830|
|Selling, general and administrative||20,520||14,282||61,634||37,067|
|Total costs and expenses||70,630||58,886||212,319||164,609|
|Loss from operations||(10,138)||(42,104)||(29,106)||(99,044)|
|Interest and other income, net||27||45||393||249|
|Loss before income taxes||(21,684)||(53,078)||(63,006)||(131,461)|
|Provision for income taxes||26||-||93||-|
|Basic and diluted net loss per share||$||(0.17)||$||(0.42)||$||(0.49)||$||(1.05)|
|Shares used in computing basic and diluted net loss per share||130,851||126,260||129,093||125,019|
|Condensed Consolidated Balance Sheet Data|
|September 30,||December 31,|
|Cash, cash equivalents, and short-term marketable securities||$||243,599||$||277,594|
|Accounts receivable, net||16,540||6,415|
|Deferred revenue – Product revenues||-||2,332|
|Convertible senior notes||315,874||298,193|
|Convertible subordinated notes||18,725||17,960|
|Total stockholders’ deficit||(219,950)||(227,077)|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV